Financing - August 12, 2024
Lundbeck and Takeda modify collaboration agreement
Lundbeck has announced that in support of Lundbeck’s Focused Innovator strategy with the aim to create financial flexibility and reallocate resources to other growth opportunities, it has been agreed with Takeda to modify the current collaboration in the U.S. from a co-promotion, cost-sharing, revenue-sharing, and royalty setup to a royalty-based only model effective 1 January […]
New Market - August 7, 2024
The European Commission has granted a full marketing authorization for Kinpeygo
Calliditas Therapeutics has announced that the European Commission has granted a full marketing authorization for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). The granting of the full approval results in a significantly broader label for patients with primary IgAN, moving from a urine protein excretion (UPCR) limitation of > 1.5g/g […]
Financing - July 11, 2024
Orion and MSD announce mutual exercise of option
Orion Corporation and MSD have announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat, an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for MSD. “The conversion of this collaboration into a license agreement allows […]
Biotech Business - July 3, 2024
Genmab’s Epcoritamab receives positive CHMP opinion
Genmab has announced that the EMA Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of conditional marketing authorization of epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or […]
Acquisition - July 3, 2024
Zelmic becomes part of CTR Group
Center for Translational Research (CTR) expands by acquiring Zelmic, the GMP-approved Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), specialized in development of topical and transdermal pharmaceutical formulations and drug delivery. The acquisition further expands CTRs portfolio, within pharmaceutical, regulatory, and clinical development to the CTR group, the company states. “The addition […]
Biotech Business - July 1, 2024
Oncopeptides selects first candidate drug from its SPiKE platform
Oncopeptides has announced that the first candidate drug based on the company’s platform for Small Polypeptide based innate Killer Engagers (SPiKE) has been selected. The SPiKE platform uses multi-specific constructs, able to bind to multiple targets simultaneously. The first drug candidate, OPSP1, is a bi-specific construct designed to both engage natural killer cells, a type […]
